Drug Trial Radar · NCT04196530
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 21, 2019
Primary completion
Jul 31, 2024
Study completion Aug 15, 2024
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Seven and Eight
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
Conditions
- Tumor, Solid
Interventions
BDB001 (EIK1001)Drug
BDB001 (EIK1001) is an immunotherapy agent.
AtezolizumabDrug
Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: incidence of adverse events and any dose limiting toxicityTime frame: up to 21 months
- Determine Maximum Tolerated Dose (MTD) or recommended Phase 2 Dose (RP2D)Time frame: from first dose to 21 days after first dose for each patient
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Angeles Clinic
Los Angeles, California
Florida Cancer Specialists
Sarasota, Florida
Tennessee Oncology
Nashville, Tennessee
NEXT Oncology
San Antonio, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.